Preventing Air and Water Pollution
As a pharmaceutical company handling various chemical substances, the Daiichi Sankyo Group considers proper management of chemical substances as an important initiative and issue. To prevent air and water pollution, the group company plants outside of Japan, including Daiichi Sankyo Pharmaceutical (Beijing), Daiichi Sankyo Pharmaceutical (Shanghai), Daiichi Sankyo Europe (Germany), and Daiichi Sankyo Brasil Farmaceutica regularly monitor their emissions to ensure compliance with the laws and regulations of each country and region. In Japan, the Group has established voluntary control standards that are stricter than legal requirements and properly monitors the emissions at plants and research & development (R&D) centers in Group companies.
SOx Emissions (Entire Group)
NOx Emissions (Entire Group)
BOD (Entire Group)
COD (Entire Group)
Preventing Soil and Groundwater Contamination and Countermeasures
The Group makes efforts to prevent soil and groundwater contamination at plants and research centers. In Japan, when an investigation is required based on the Soil Contamination Countermeasures Act and related prefectural ordinance, we conduct the appropriate investigation according to the laws and regulations on discussion with the governmental offices.
Furthermore, we also conduct investigations according to the laws and regulations even in the cases where mandatory regulations do not apply, such as the closing of offices and change of using purpose.
If contamination occurs, we report it to the related government offices and properly disclose information to members of the surrounding community, and take appropriate measures, such as prevention of diffusion and purification. according to the extent of contamination. The offices that have already taken measures, such as purification, continue to monitor and report the result of analysis to governmental offices and community members.
Progress of Measures for Soil Purification
|Shinagawa R&D Center (Shinagawa-ku, Tokyo)
||We performed a soil investigation associated with the construction of new research facilities according to Tokyo municipal ordinance. As a result, contamination was found in a part of soil. Thus we performed purification work appropriately, including discussion with the governmental offices.
|The site of former Yasugawa plant (Yasu City, Shiga)
|We have been continuously monitoring the groundwater since we completed on-site environmental improvement work in 2006. As a result, contamination was found in part of the soil. We are currently conducting a soil investigation in consultation with regulatory authorities to perform appropriate purification work. We also confirmed the presence of mercury used as a material for pesticides that exceeded environmental standards on the grounds of the former plant site in 1993. Since then, we have installed a robust underground storage facility in adherence to regulatory guidance to manage the soil appropriately. Although there have been no reports of leakage or health issues to date, we decided to remove the storage facility in view of increasing safety and security in the region and in response to requests from the local community, and we issued a press release announcing our decision in April 2020. We will consult and coordinate with the relevant parties to ensure that the removal work will cause no negative impact on the surrounding environment.
Prevention of Noise, Vibration, and Offensive Odors
We conduct appropriate measures and continuous monitoring to comply with the laws and regulations related to noise, vibration, and offensive odor.
Appropriate Management and Emission and Transfer Control of Chemical Substances
We manage chemical substances that may adversely affect human health or the ecosystem based on the PRTR*1 system provided in the Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof. The amount of chemical substances handled that are subject to the PRTR system in FY2020 decreased to 2,063 metric tons from 2,301 metric tons in FY2019.
Emissions to air and water decreased to 3.4 metric tons in FY2020 compared to 4.4 in metric tons FY2019.
There was no transport, import, export, or treatment of waste that was deemed hazardous or any transport of waste that was shipped internationally as described in the terms of the Basel Convention Annex I, II, III, and VIII.
*1Pollutant Release Transfer Register
Emission/Transfer Chemical Substances (Group in Japan)
(Unit: metric ton; mg-TEQ for dioxins)
Storage and Usage of PCB Contaminants
|Fluorescent lamp ballasts, etc.
* We have sorted and weighed the PCB contaminated matter and have registered the shipment to be treated by JESCO , an interim storage and environmental safety corporation. We have already disposed of all low concentration PCBs.
Evaluation of the Environmental Impact of Pharmaceutical Products
The Daiichi Sankyo Group conducts the necessary environmental impact assessments for its pharmaceuticals based on the guidelines of relevant countries and implements measures as appropriate.
The Group realizes that one of the sustainability risks associated with its business activities is the possible negative impacts of pharmaceutical manufacturing and its by-products on the environment. There have been incidents in the past in which by-products of pharmaceutical manufacturing were detected in rivers and other natural environments. The Group aware that social concern is rising with regard to this issue as well as its potential environmental repercussions. The Group watches closely such social responses and the global trend toward promotion of initiatives for EPS*2 by the European Federation of Pharmaceutical Industries and Associations (EFPIA).
We believe that we need to continuously coordinate with governments, industry organizations, and research institutions to examine more appropriate risk evaluations and risk management.
*2EPS (Eco-Pharmaco-Stewardship): Voluntary initiatives to prevent environmental impacts throughout the lifecycle of pharmaceuticals and eco-friendly product management.
Environmental Impact Assessment of the Manufacturing Processes
As the changes in manufacturing processes for pharmaceutical products are regulated by pharmaceutical related laws and regulations, such changes require considerable time and effort. Accordingly, it is important to discuss and evaluate changes not only from the view of quality and cost, but also from a wide range of perspectives including impact on environment.
When developing manufacturing processes for new products, the Daiichi Sankyo Group uses its own evaluation indicators*3 to determine the impact of these processes on the environment. This approach is based on the concept of eco-friendly green chemistry. Through this approach, we aim to create manufacturing processes that are considerate of the sustainability of the natural environment by developing new synthetic processes, preventing pollution, and reducing resource and energy consumption.
For manufacturing processes that produce waste, we discuss and evaluate methods through which the waste can be collected and reused as well as methods of treating this waste that are highly safe and have a low environmental impact.
The result of this research leads to a great reduction of the environmental impact of the final manufacturing process (industrialized manufacturing method) compared with the impact when this research had just begun.
*3Indicators established by scoring the items such as the safety or toxicity, operating condition, and waste volumes, etc., of solvents or reagents
Initiatives for Biodiversity Conservation
The Group’s Basic Environmental Management Policy and the Mid-term Environmental Management Policy stipulate that business activities must consider biodiversity and ecosystem services. The Group has established the Basic Biodiversity Principles and Action Guidelines based on these policies. When this was established, the Group surveyed its initiatives on biodiversity, the use of natural resources, and status of efforts to comply with the Cartagena Protocol both inside and outside of Japan. Additionally, the Group assessed the relationship between its business activities and biodiversity and identified issues through an analysis of the Group’s risks and opportunities. (Please refer to the diagram “Map of corporate activities and biodiversity” below.)
The Daiichi Sankyo Group believes that biodiversity conservation and sustainable use of ecosystem services are essential in performing business. We promote raising awareness and understanding of employees, as well as the strengthening of environmental conservation activities in collaboration with business partners and private groups, to procure materials with less environmental burden, and to socially contribute towards biodiversity conservation.
Basic Biodiversity Principles and Action Guidelines
- Our Basic Environmental Management Policy states that, “Safeguarding the environment is the bedrock of all Group operational management.” We have
therefore acted to prevent pollution and global warming and contribute to recycling. Through our initiatives, we have used biological resources properly to
minimize the impacts of our operations on biodiversity and have sustainably reduced chemical and other discharges.
- We will continue striving to preserve biodiversity and respect the principles of the Convention on Biological Diversity by adhering to the following
Biodiversity Action Guidelines, thereby enhancing social sustainability.
Actively promote to address biodiversity conservation in all business activity
- Under take ongoing endeavors to avoid or reduce operational impacts on biodiversity, devoting particular attention to lowering the environmental impacts of air and water emissions and wastes.
Identify the biodiversity impacts of ecosystem services, using those services sustainably
- Recognize the operational importance of ecosystem services while understanding and minimizing their impacts on biodiversity, using those services sustainably.
Use genetically modified organisms responsibly
- Maintain biosafety by continuing to responsibly use genetically modified organisms in drug discovery and production in keeping with the Cartagena Protocol on Biosafety and national laws and ordinances.
Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization
- Comply with the Convention on Biological Diversity, the Bonn Guidelines, and other relevant rules to access and utilize genetic resources of the provider countries appropriately and to share benefits arising from their utilization in a fair and equitable manner.
Communicate with stakeholders and improve in-house awareness
- Foster biodiversity preservation by communicating and liaising better with public and private entities.
- Educate employees to better understand how operations affect biodiversity and encourage internal and external efforts to safeguard biodiversity.
Map of Corporate Activities and Biodiversity
An enlargeable image opens in a separate window
We assess the ecological footprint (EF), an indicator of biodiversity, jointly with experts from the NGO Global Footprint Network, to examine all environmental burdens in the business activities of Group companies in Japan. The assessed EF is used as a comprehensive indicator of environmental burdens, including those related to biodiversity, by reviewing and monitoring long-term changes in the relationship between the reduction of environmental burdens and biodiversity conservation (trade-off) in the Group.
This initiative has been recognized as an action for achieving the Aichi Target (20 targets) that was adopted at COP10 (the 10th Meeting of the Conference of the Parties to the Convention on Biological Diversity in Nagoya) and has been registered on the Nijyu-Maru Project as well. In addition, it was introduced as an example of monitoring biodiversity in the Guidelines for Private Sector Engagement in Biodiversity (Second Edition) issued by the Ministry of the Environment of Japan.
Initiatives for Biodiversity Conservation
Conservation for rare species of plants
To preserve the golden orchid (designated as critically endangered Type II in the Japanese Ministry of the Environment’s Red Data Book) and the silver orchid, we have prohibited entry into the forested area of the property at the Tatebayashi Biopharmaceuticals Center where the plant naturally grows (approximately 1,000 m2). The continued conservation effort has been resulted in an increase in the population of the species and expansion of breeding range.
Greening in harmony with the surrounding environment
The Kitamoto Office of Daiichi Sankyo Biotech Co., Ltd. engages in environmental conservation that considers the surrounding natural environment and ecosystem and implements sound insulation and greening in harmony with the neighboring Kitamoto Nature Observation Park.
Recognized for its various diversity-friendly initiatives, the office was given the 7th Sainokuni Green Plan Award in 2015. The award is granted by Saitama Prefecture to facilities that have achieved excellent greening and sound maintenance.
The office continues to engage in environmental conservation through greening and other ecosystem protection measures.
Implementation of WET testing
With the purpose of assessing the impact of water discharged from operation sites, in FY2020, we continued to conduct WET testing*4 at all plants and research facilities in Japan (eight operation sites). As a result, we confirmed that the discharged water has no serious impact on aquatic organisms in rivers, etc. In FY2021, we plan to conduct WET testing once at our plants and research facilities in Japan as we do every year and at an additional three plants of Daiichi Sankyo Chemical Pharma to promote appropriate wastewater management and improve the quality of discharged water.
*4 Whole Effluent Toxicity Test. A testing method that utilizes the biological responses of fish, daphnia, and seaweed to determine the total toxicity of discharged water.
Extracting water for the WET test